Cargando…

Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms

PURPOSE: The β(¯)-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borgna, Francesca, Haller, Stephanie, Rodriguez, Josep M. Monné, Ginj, Mihaela, Grundler, Pascal V., Zeevaart, Jan Rijn, Köster, Ulli, Schibli, Roger, van der Meulen, Nicholas P., Müller, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921065/ https://www.ncbi.nlm.nih.gov/pubmed/34625828 http://dx.doi.org/10.1007/s00259-021-05564-0

Ejemplares similares

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
por: Juget, Frédéric, et al.
Publicado: (2022)

Terbium-149 for targeted alpha therapy
por: Borgna, Francesca, et al.
Publicado: (2021)

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
por: Müller, Cristina, et al.
Publicado: (2016)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

(161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic
por: Favaretto, Chiara, et al.
Publicado: (2023)

Terbium-149 for targeted alpha therapy
por: Grundler, Pascal, et al.
Publicado: (2023)

Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging
por: Favaretto, C., et al.
Publicado: (2021)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with $^152$Tb-DOTATOC
por: Baum, Richard P, et al.
Publicado: (2017)

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
por: Hemmingsson, Jens, et al.
Publicado: (2022)

(47)Sc as useful β(–)-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes
por: Domnanich, Katharina A., et al.
Publicado: (2017)

Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer
por: Bernhardt, Peter, et al.
Publicado: (2021)

Establishment of a clinical SPECT/CT protocol for imaging of (161)Tb
por: Marin, I., et al.
Publicado: (2020)

Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix
por: Saponjski, Jelena, et al.
Publicado: (2020)

Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms
por: Inaba, Yoshitaka, et al.
Publicado: (2022)

Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
por: Cassells, Irwin, et al.
Publicado: (2021)

Therapeutic Potential of (47)Sc in Comparison to (177)Lu and (90)Y: Preclinical Investigations
por: Siwowska, Klaudia, et al.
Publicado: (2019)

Primary hepatic neuroendocrine neoplasm diagnosed by somatostatin receptor scintigraphy: A case report
por: Akabane, Miho, et al.
Publicado: (2022)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Chemical Purification of Terbium-155 from Pseudo-Isobaric Impurities in a Mass Separated Source Produced at CERN
por: Webster, Ben, et al.
Publicado: (2019)

Chemical Purification of Terbium-155 from Pseudo-Isobaric Impurities in a Mass Separated Source Produced at CERN
por: Webster, Ben, et al.
Publicado: (2019)

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
por: Gatto, Federico, et al.
Publicado: (2019)

Unknown‑primary neuroendocrine neoplasms diagnosed by short‑acting somatostatin test: Case series in one institution
por: Chang, Tsung-Kun, et al.
Publicado: (2022)

Somatostatin receptor expression in parathyroid neoplasms
por: Storvall, Sara, et al.
Publicado: (2019)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Case report: Peritumoral hepatic steatosis in a patient with a metastatic somatostatin-producing oligosymptomatic neuroendocrine neoplasm
por: Shao, Yuming, et al.
Publicado: (2022)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm
por: Barbieri, Federica, et al.
Publicado: (2013)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
por: Müller, Cristina, et al.
Publicado: (2018)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_no99li236pr1qvbp7j2e65t7ee